AstraZeneca’s (AZN) supplemental Biologics License Application for Imfinzi has been accepted and granted Priority Review in the U.S. for the treatment of patients with muscle-invasive bladder cancer, the company announced.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca announces FDA approval for Imfinzi
- AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
- AstraZeneca appoints Iskra Reic as Executive Vice President, International
- AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List
- AstraZeneca announces results from CAPItello-281 trial